StockData
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

COGNITION THERAPEUTICS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.73−0.00 (-0.33%)

Close on Oct 19, 2026

Market cap
$65.92M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026During market hours–$-0.04–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026During market hours–$-0.05–
Q4 FY2025
Ended Dec 31, 2025
Mar 26, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025Before market open–$-0.06–
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours–$-0.11–
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025Before market open–$-0.14–
Q4 FY2024
Ended Dec 31, 2024
Mar 20, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024Before market open–$-0.25–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open–$-0.18–
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024Before market open–$-0.27–
Q4 FY2023
Ended Dec 31, 2023
Mar 11, 2024During market hours–––

Press releases

Announcements Cognition Therapeutics filed with the SEC